Hormone Resistant Prostate Cancer Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Abiraterone Acetate, Olaparib, and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer With DNA Repair Defects
Conditions: Prostate Cancer Metastatic Castration-Resistant; Abnormal DNA Repair; Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma; Stage IV Prostate Cancer Interventions: Drug: Olaparib; Drug: Abiraterone Acetate; Drug: Prednisone Sponsors: Northwestern University; AstraZeneca; National Cancer Institute (NCI) Not yet recruiting - verified January 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 3, 2017 Category: Research Source Type: clinical trials
